Phase 2 RCT: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer.

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)

Commentary: Prolonged PFS Observed With Addition of Atezolizumab to FOLFOXIRI and Bevacizumab for Metastatic CRC – Cancer Network

Commentary on Twitter

In phase II AtezoTRIBE study of the addition of atezolizumab to first-line FOLFOXIRI + bevacizumab improved PFS in pts with pMMR/MSS mCRC (median 13.1 vs 11.5 months; adjusted HR 0.70, 80% CI 0.57–0.87; P = 0.018): https://t.co/0dkRxjvjsx #ImmunoOnc #CRCSM

— NatureRevClinOncol (@NatRevClinOncol) May 31, 2022